<?xml version='1.0' encoding='utf-8'?>
<document id="12269842"><sentence text="Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment." /><sentence text="A substantial percentage of infants, children and adolescents experience gastroesophageal reflux disease (GERD) and its accompanying symptoms, as well as disease complications" /><sentence text=" The diagnosis of GERD in children is made based upon the child's history, and data derived primarily from pH monitoring tests and endoscopy" /><sentence text=" In those children with confirmed reflux disease, the options for management parallel those recommended in adult patients, with the first step consisting of lifestyle changes" /><sentence text=" Surgical procedures may also be performed; however, these are rarely recommended prior to an adequate course of pharmacologic therapy, and appropriate case selection is important" /><sentence text=" Among the current pharmacotherapeutic options available in the US, the prokinetic agents and the acid-inhibitory agents (histamine-2 receptor antagonists, proton pump inhibitors) are the most widely used" /><sentence text=" The clinical utility of the prokinetic agents has been limited by the recent withdrawal of cisapride from the US marketplace and the potential for irreversible central nervous system complications with metoclopramide"><entity charOffset="92-101" id="DDI-PubMed.12269842.s7.e0" text="cisapride" /><entity charOffset="203-217" id="DDI-PubMed.12269842.s7.e1" text="metoclopramide" /><pair ddi="false" e1="DDI-PubMed.12269842.s7.e0" e2="DDI-PubMed.12269842.s7.e0" /><pair ddi="false" e1="DDI-PubMed.12269842.s7.e0" e2="DDI-PubMed.12269842.s7.e1" /></sentence><sentence text=" Numerous clinical studies performed in adults, and several studies involving children, have demonstrated that the proton pump inhibitors are more effective than the histamine-2 receptor antagonists in the relief of GERD symptoms and healing of erosive esophagitis" /><sentence text=" In children, omeprazole and lansoprazole may be administered as the intact oral capsule, or in those who are unable or unwilling to swallow, the granule contents of the capsule may be mixed with soft foods (e"><entity charOffset="14-24" id="DDI-PubMed.12269842.s9.e0" text="omeprazole" /><entity charOffset="29-41" id="DDI-PubMed.12269842.s9.e1" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.12269842.s9.e0" e2="DDI-PubMed.12269842.s9.e0" /><pair ddi="false" e1="DDI-PubMed.12269842.s9.e0" e2="DDI-PubMed.12269842.s9.e1" /></sentence><sentence text="g" /><sentence text=" apple sauce) or fruit drinks/liquid dietary supplements prior to oral administration with no detrimental effects on pharmacokinetics, bioavailability, or pharmacodynamics" /><sentence text=" Studies performed with omeprazole and lansoprazole in children have shown pharmacokinetic parameters that closely resemble those observed in adults"><entity charOffset="24-34" id="DDI-PubMed.12269842.s12.e0" text="omeprazole" /><entity charOffset="39-51" id="DDI-PubMed.12269842.s12.e1" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.12269842.s12.e0" e2="DDI-PubMed.12269842.s12.e0" /><pair ddi="false" e1="DDI-PubMed.12269842.s12.e0" e2="DDI-PubMed.12269842.s12.e1" /></sentence><sentence text=" In over a decade of use in adults, the proton pump inhibitor class of agents has been found to have a good safety profile" /><sentence text=" Studies involving children have also shown these agents to be well tolerated" /><sentence text=" In numerous drug-drug interaction studies performed with these two proton pump inhibitors, relatively few clinically significant interactions have been observed" /><sentence text="" /></document>